Clinical Trial Update: A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies [Phase 2]

View source ↗

Summary

Phase II open-label study evaluating olutasidenib as post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies; recruitment ongoin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloid Malignancies

Drugs mentioned

• Olutasidenib (olutasidenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloid Malignancies | Phase 2 | Status: RECRUITING